Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.000
-0.040 (-3.85%)
At close: Dec 20, 2024, 4:00 PM
1.020
+0.020 (2.00%)
After-hours: Dec 20, 2024, 6:37 PM EST
Immunic Employees
Immunic had 77 employees as of December 31, 2023. The number of employees increased by 11 or 16.67% compared to the previous year.
Employees
77
Change (1Y)
11
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,258,494
Market Cap
90.08M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| FONAR | 561 |
| Harvard Bioscience | 416 |
| Veru Inc. | 189 |
| Adverum Biotechnologies | 121 |
| electroCore | 68 |
| Journey Medical | 41 |
| Zentek | 24 |
| Avalo Therapeutics | 19 |
IMUX News
- 25 days ago - Immunic, Inc. to Participate in Investor Conference in December - PRNewsWire
- 5 weeks ago - Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PRNewsWire
- 6 weeks ago - Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - PRNewsWire
- 7 weeks ago - Immunic to Participate in Industry, Scientific and Investor Conferences in November - PRNewsWire
- 2 months ago - Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - PRNewsWire
- 3 months ago - Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis - PRNewsWire